Last reviewed · How we verify

NCT06289816

Spleen Preserving Surgery for Splenic Hydatidosis: A Cohort Study on Short and Long-Term Outcomes

Completed Last updated 4 March 2024
What this trial tests

trial testing Minimally Invasive Surgery in Spleen-Preserving Surgery in 18 participants. Completed in 30 June 2021.

Timeline
1 January 2015
Primary endpoint
30 June 2021
30 June 2021

Quick facts

Lead sponsorYarmouk University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment18
Start date1 January 2015
Primary completion30 June 2021
Estimated completion30 June 2021
Sites1 location across Jordan

Drugs / interventions tested

Conditions studied

Sponsor

Yarmouk University

Who can join

Adults 18 to 70, any sex, with Spleen-Preserving Surgery or Echinococcus Granulosus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This retrospective cohort study examines the effectiveness of minimally invasive spleen-preserving surgeries compared to total splenectomy for treating primary splenic hydatidosis in Jordan. Covering 18 patients from January 2015 to June 2021, the research highlights similar recurrence rates between both surgical approaches, emphasizing the benefits of spleen preservation in maintaining immune function and reducing septic risks, particularly in pediatric patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Minimally invasive spleen-preserving surgery to treat primary splenic hydatidosis: short and long-term outcomes: a cohort study.
    Aljaiuossi A, Ba-Shammakh SA, Bani Hani M, Al-A'athal MS, et al · · 2024 · cited 2× · PMID 39238958 · DOI 10.1097/ms9.0000000000002320

Verify or expand the search:

Other trials of Minimally Invasive Surgery

Trials testing the same drug.

Other Yarmouk University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06289816.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing